2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5001 Anti-leukemic activity of FOLR1-targeting with mirvetuximab soravtansine in acute myeloid leukemia

Katherine Tarlock I, MD, Danielle C. Kirkey, MD2, Melia Blankenfeld, BS3, Grace Hawkins4, Rhonda E. Ries, MA5, Challice Bonifant, MD, PhD6, Alan Friedman, MD7, John Horan, MD8, Soheil Meshinchi, MD, PhD9
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
7 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
8 University of Rochester Medical Center/Golisano Children’s Hospital, Rochester, New York, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States

The cryptic CBFA2T3::GLIS2 (CBF-GLIS) fusion occurs in infants and very young children and identifies one of the most aggressive and lethal subtypes of AML. We discovered folate receptor alpha (FRα) to be induced in CBF-GLIS AML and expressed only on the leukemia cell surface and absent from other hematopoietic tissues, thus making it a true AML-restricted antigen. Mirvetuximab soravtansine (MIRV)/Elahere is a FRα antibody drug conjugate (ADC) with maytansinoid DM4 payload that is approved for platinum-resistant FRα + ovarian carcinoma. We evaluated the preclinical activity of MIRV in FOLR1+ AML and report on 2 patients with FOLR1+ AML who received MIRV for refractory disease.

In vitro cytotoxicity was performed on numerous cell lines with native or engineered FRα expression through lentiviral FRα vector. Cell lines with baseline FRα+ expression were 1) WSU-AML, 2) M-07e with low level expression, 3) IGROV1 ovarian carcinoma line. FOLR1 was also expressed through lentiviral transduction into FOLR1-negative Kasumi-1 and MV4;11 (Kasumi-1- FRα+; MV4;11- FRα+) with parental non-transduced cells lines used as negative controls, and overexpressed in M-07e (M-07e.FRα-OE). In CDX studies, target positive and negative cell lines were engrafted into NSG mice and treated with MIRV. Isotype control with DM4 (IC-DM4) or amatuximab ravtansine (AR; anti-mesothelin ADC with DM4 payload) were used as control.

Evaluation of MIRV across FRα+ cell lines demonstrated variable levels of efficacy with viability assessed 3 or 5 days following exposure. MIRV was active in MV4;11- FRα+ cells with an IC50 of 0.55nM vs. 13nM in parental MV4;11. MIRV was also active in M-07e and M-07e- FRα-OE cells with IC50s of 36.5 and 43.6nM respectively, compared to > 100nM for both cell lines following exposure to AR. In contrast, IC50s following exposure to MIRV were nearly identical (47nM) among Kasumi-1- FRα+ and parental. Similarly, for the WSU cell line, there was no increased cytotoxicity following exposure to MIRV compared to IC-DM4 (IC50: 20.5 vs. 23.4nM, respectively). We subsequently evaluated the anti-leukemic activity of DM4 in our cell lines with 3-day cytotoxicity read outs. In the IGROV1 cell line as a positive control, free DM4 was highly potent with an IC50 of 0.8nM, MIRV exposure resulted in an IC50=7.52nM, followed by IC-DM4 with an IC50=50nM. In M-07e cells, DM4 was also highly cytotoxic with IC50<0.3nM, with an IC50 of 16.7 vs 65nM following exposure to MIRV and IC-DM4 respectively. In M-07e.FRα-OE CDX, treatment with MIRV 5 mg/kg x 3 resulted in significant reductions in tumor burden and prolonged survival (median survival of 34 days in untreated, 37 in AR treated, 51 in MS treated, p<0.001). Ultimately, all MS treated mice developed AML and succumbed to disease.

In addition to the preclinical studies, two patients with refractory FRα+ AML have been treated with MIRV. Patient #1, a 20-month-old, with RBM15-MKL1 FRα+ AMKL was refractory to 3 induction attempts and had >90% disease and received MIRV 6 mg/kg. Flow cytometric assessment in the setting of persistent circulating disease 10 days after MS showed absence of detectable FRα on AML blasts. The patient died of progressive AML. Patient#2, a 2-year-old with CBF-GLIS FRα+ AML was refractory to 2 courses of induction chemotherapy with 0.8% MRD by flow and 0.4% of the CBF-GLIS fusion detected by qRT-PCR and received 2 doses of MIRV (6 mg/kg q 21 days). Therapy was well tolerated and marrow evaluation after MIRV showed no evidence of MRD or PCR detectable disease and the patient proceeded to allogeneic HCT and remains alive in remission and is receiving post-HCT MIRV maintenance.

Given the shared expression of FRα on ovarian carcinoma and other malignancies, ADCs developed and available for these indications also have potential for clinical activity in FRα+ AML. We show that MIRV has on-target anti-leukemic activity in multiple FRα+ AML cell lines and CDX. Reasons for variability of response may include variation in antigen density, internalization of the payload, leukemia-specific variable tubulin inhibitor potency, and the potential for immune escape. The potential efficacy and limitations of MIRV therapy in our preclinical data are reflected in the patient experience to date and more clinical data is needed to better understand the true efficacy of MIRV in this patient population. 

Katherine Tarlock I, MD: Seattle Children's Hospital - Current Employment